Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Smith & Nephew Sees Slower Sales Growth on Weak Implants Demand (Bloomberg) +++ SMITH & NEPHEW Aktie -4,63%

CRISPR THERAPEUTICS Aktie

 >Aktienkurs 
43.53 EUR    +1.1%    (TradegateBSX)
Ask: 43.53 EUR / 228 Stück
Bid: 43 EUR / 231 Stück
Tagesumsatz: 132 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: +4,3%
1 Monat: -17,2%
3 Monate: -3,1%
6 Monate: -1,3%
1 Jahr: -12,1%
laufendes Jahr: -6,4%
>CRISPR THERAPEUTICS Aktie
Name:  CRISPR THERAPEUTICS
Land:  Schweiz
Sektor:  Gesundheit
ISIN/ Wkn:  CH0334081137 / A2AT0Z
Symbol/ Ticker:  1CG (Frankfurt) / CRSP (NASDAQ)
Kürzel:  FRA:1CG, ETR:1CG, 1CG:GR, NASDAQ:CRSP
Index:  -
Webseite:  https://crisprtx.com/
Profil:  CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing-based medicines for serious diseases. The company develops therapies using its proprietary CRISPR/Cas9 platform, which enables precise changes to DNA and supports a portf..
>Volltext..
Marktkapitalisierung:  4053.97 Mio. EUR
Unternehmenswert:  2621.92 Mio. EUR
Umsatz:  3.56 Mio. EUR
EBITDA:  -460.9 Mio. EUR
Nettogewinn:  -493.33 Mio. EUR
Gewinn je Aktie:  -5.39 EUR
Schulden:  683.45 Mio. EUR
Liquide Mittel:  367.66 Mio. EUR
Operativer Cashflow:  -347.06 Mio. EUR
Bargeldquote:  17.92
Umsatzwachstum:  -89.8%
Gewinnwachstum:  -38.04%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CRISPR THERAPEUTICS
Letzte Datenerhebung:  04.08.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 96.45 Mio. St.
Frei handelbar: 92.84%
Leerverk. Aktien: 20.54%
Rückkaufquote: -21.56%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Buy
Kursziel: 76.34%
Bewertung:
KGV: -
KGV lG: -
KUV: 1115.96
KBV: 2.55
PEG-Ratio: -0.2
EV/EBITDA: -
Rentabilität:
Bruttomarge: -5283.4%
Gewinnmarge: -13856.54%
Operative Marge: -13408.29%
Managementeffizenz:
Gesamtkaprendite: -23.24%
Eigenkaprendite: -31.21%
>Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung
 
04.08.26 - 02:30
 CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
 
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
03.08.26 - 22:21
 CRISPR Therapeutics GAAP EPS of -$0.94 beats by $0.23, revenue of $10.18M beats by $2.75M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 22:18
 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire EN)
 
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026....
27.07.26 - 17:31
 CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
 
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
25.07.26 - 01:45
 CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know (Zacks)
 
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.08% shift from the previous trading day....
22.07.26 - 12:00
 Cathie Wood′s $362 Million CRISPR Therapeutics Bet Isn′t Just Bold -- It′s Backed by a Catalyst Many Investors Are Underrating (Fool)
 
This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far....
21.07.26 - 08:45
 CRISPR Therapeutics-Aktie: Steht jetzt der nächste Kursschub bevor? (Sharedeals)
 
Die Aktie von CRISPR Therapeutics hat in den vergangenen Wochen deutlich an Wert verloren, während das Unternehmen seine Entwicklungspipeline konsequent ausgebaut hat. Mit mehreren anstehenden Studiendaten und Programmfortschritten könnte sich in den kommenden Quartalen jedoch neues Kurspotenzial ergeben. Breite Aufstellung in der Geneditierung CRISPR Therapeutics zählt zu den führenden Unternehmen im Bereich der CRISPR/Cas9-Gentherapie und […] The post CRISPR Therapeutics-Aktie: Steht jetzt der nächste Kursschub bevor? first appeared on sharedeals.de....
17.07.26 - 01:15
 Here′s Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market (Zacks)
 
CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close....
11.07.26 - 01:45
 CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts (Zacks)
 
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session....
10.07.26 - 19:36
 3 Reasons to Buy CRISPR Therapeutics Stock (Fool)
 
The company's innovative qualities may pay rich dividends down the road....
08.07.26 - 12:24
 A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics (Fool)
 
This new technology could one day significantly expand the market for gene-editing biotechs....
08.07.26 - 01:45
 CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors (Zacks)
 
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day....
07.07.26 - 20:12
 Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now (Fool)
 
There's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis....
07.07.26 - 17:12
 CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? (Fool)
 
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet....
06.07.26 - 14:00
 CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here's how their financials and risk profiles compare....
27.06.26 - 12:24
 CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles....
18.06.26 - 15:24
 Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year (Fool)
 
The opportunity is enormous, but uncertainty remains....
18.06.26 - 01:45
 CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to Note (Zacks)
 
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $53.09, indicating a +2.06% shift from the previous trading day....
12.06.26 - 01:45
 CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts (Zacks)
 
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wenn wir nur das Unrecht hassen und nicht diejenigen, die es tun, werden wir unsere Kampfgenossen und unsere Feinde lieben. - Freifrau Marie von Ebner-Eschenbach
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!